Neogen Corporation (NEOG) Stock Price & Analysis
Neogen Corporation (NEOG) closed at USD 12.19 on Friday, October 23, 2026, up 1.75% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 11.98; the Oct 23, 2026 session ranged USD 11.82–12.33 on volume of 2,652,349 shares. Market capitalization is $2.66B, with a 52-week range of USD 5.37–14.26 (NMS). Source: Nexqual, retrieved October 23, 2026 at 21:05 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NEOG.md
Key facts (NEOG)
- Last four reported quarters (through Aug 31, 2026): revenue $884M, net income -$56.1M (-6.3% margin), free cash flow $49.8M (SEC filings).
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $10K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 14 (range 14–14).
- Total return with dividends: 1Y +96.9% vs S&P 500 +13.4%; 5Y -71.2% vs S&P 500 +76.9%.
- Next earnings: 2026-10-06, EPS estimate USD 0.06, revenue estimate $223M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NEOG)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $527M | $822M | $924M | $895M | $870M | $884M |
| Gross profit | $243M | $406M | $464M | $421M | $409M | — |
| Operating income | $58.6M | $37.5M | $58.6M | -$1.06B | -$21.6M | -$7.4M |
| Net income | $48.3M | -$22.9M | -$9.4M | -$1.09B | -$7.9M | -$56.1M |
| EPS (diluted) | $0.45 | -$0.12 | -$0.04 | -$5.03 | -$0.04 | — |
| Free cash flow | $43.6M | -$24.7M | -$76.1M | -$46.4M | $31.9M | $49.8M |
| Gross margin | 46.1% | 49.4% | 50.2% | 47.1% | 46.9% | — |
| Operating margin | 11.1% | 4.6% | 6.3% | -118.6% | -2.5% | -0.8% |
| Net margin | 9.2% | -2.8% | -1.0% | -122.1% | -0.9% | -6.3% |
| Revenue growth | +12.5% | +56.0% | +12.4% | -3.2% | -2.7% | — |
| Cash + short-term investments | $381M | $246M | $171M | $129M | — | — |
| Total debt | $0K | $885M | $891M | $894M | $794M | — |
Fiscal years end May. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Aug 31, 2026) (NEOG)
P/S 3.0x · P/FCF 53.4x · P/B 1.3x · FCF yield 1.87% · Earnings yield -2.11%
Insider purchases (SEC Form 4, open-market, last ~7 months) (NEOG)
2 purchases, $10K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-10-09 | Nassif Mikheal | CEO | 505 | $6K | 11.95 | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-04 | Nassif Mikheal | CEO | 370 | $4K | 11.81 | Too little history (no open-market trades in 2023 or 2024) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NEOG)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 14 (low 14, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-30 | Guggenheim | Target raised | Buy | $12 → $14 |
| 2026-08-26 | Piper Sandler | Upgrade | Neutral → Overweight | $13 → $14 |
| 2026-08-03 | Piper Sandler | Target raised | Neutral | $11 → $13 |
Total return (dividends reinvested) (NEOG)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +96.9% | -71.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +97.4% | -22.1% |
| Volatility (annualized) | 55.2% | 52.5% |
| Max drawdown | -27.7% (Feb 2026→May 2026) | -90.3% (Dec 2021→Apr 2025) |
NEOG revenue by business segment (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Food Safety | $163.2M | 73.2% | +7.3% |
| Animal Safety | $59.6M | 26.8% | +4.4% |
| Total revenue | $222.8M | 100% | — |
NEOG revenue by product line (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $196.0M | 88.0% | +6.5% |
| Indicator Testing & Culture Media | $85.6M | 38.4% | +11.5% |
| — Bacterial & General Sanitation (part of Indicator Testing & Culture Media) | $44.6M | 20.0% | +7.2% |
| — Service (part of Indicator Testing & Culture Media) | $26.8M | 12.0% | +6.8% |
| — Veterinary Instruments & Consumables (part of Indicator Testing & Culture Media) | $14.1M | 6.3% | +18.5% |
| Natural Toxins & Allergens | $19.3M | 8.7% | -3.5% |
| Animal Care & Other | $7.7M | 3.5% | +1.3% |
| Genomics Services | $6.7M | 3.0% | +19.6% |
| Biosecurity Products | $4.6M | 2.1% | -20.7% |
| Other | $2.4M | 1.1% | +4.3% |
| Life Sciences | $1.6M | 0.7% | -15.8% |
| Total revenue | $222.8M | 100% | — |
NEOG revenue by region (quarter ended Aug 31, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Non Us | $112.7M | 50.6% | +5.2% |
| United States | $110.1M | 49.4% | +7.8% |
| Total revenue | $222.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
NEOG suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | 3M (MMM) | “Further, in fiscal year 2025, we experienced negative impacts from delays in restarting full production of our sample collection product line, which we relocated from 3M into a Neogen facility.” |
| Customer | Neogen Ireland | “Neogen Ireland Ltd, headquartered in Bray, Ireland, sells products and services to our network of customers and distributors throughout Europe, the Middle East and Africa.” |
| Customer | UPS (UPS) | “We ship a significant portion of our products to customers through independent package delivery companies, such as UPS, Federal Express and DHL.” |
Quoted from the company's 10-K filed Jul 30, 2026.
NEOG customer concentration
In the period ended May 31, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-K filed Jul 30, 2026. The company does not name it.
NEOG company outlook (results filed Oct 6, 2026)
- “Financial Guidance (in millions) Current FY27 Financial Guidance Previous FY27 Financial Guidance Revenue $885 – $890 $880 – $885 Adjusted EBITDA 1 $181 – $183 $180 – $182 • The Company is increasing its financial guidance for fiscal year 2027 and is now expecting total revenue in the range of $885 million to $890 million and Adjusted EBITDA in the range of $181 million to $183 million.”
Quoted word-for-word from the SEC 8-K results press release.
NEOG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Nov 2026) | $0.06 | $0.10 | -34.5% | $223.1M | 3 |
| Next quarter (ends Feb 2027) | $0.08 | $0.07 | +25.0% | $214.3M | 3 |
| Current fiscal year (ends May 2027) | $0.33 | $0.30 | +11.1% | $888.1M | 3 |
| Next fiscal year (ends May 2028) | $0.45 | $0.42 | +7.1% | $827.7M | 2 |
NEOG options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 45.8% | ±11.1% |
| Dec 18, 2026 | 56 | 42.3% | ±14.1% |
| Jan 15, 2027 | 84 | 51.7% | ±20.6% |
| Apr 16, 2027 | 175 | 51.5% | ±29.0% |
30-day implied volatility 38.7% vs 51.3% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 21:05 UTC)
| Price | USD 12.19 |
|---|---|
| Change | ▲ 1.75% (up) |
| Previous Close | USD 11.98 |
| Open | USD 11.97 |
| Day Range | USD 11.82 – 12.33 |
| 52-Week Range | USD 5.37 – 14.26 |
| Volume | 2,652,349 shares |
| Market Cap | $2.66B |
| Exchange | NMS |
Technical Analysis (NEOG)
Nexqual's technical model rates NEOG "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 21:05 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.72 (neutral) |
| vs SMA50 | Above (USD 12.19) |
| MACD | -0.12 (negative) |
Analyst Ratings (NEOG)
Wall Street analysts rate NEOG "Buy" based on 4 analysts, with a mean price target of USD 14 (range USD 14–14), per Nexqual as of October 23, 2026 at 21:05 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 14 |
| High Target | USD 14 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (NEOG)
| Next Earnings Date | 2026-10-06 |
|---|---|
| EPS Estimate | USD 0.06 |
| Revenue Estimate | $223.05M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-08-31 | USD 0.08 vs est 0.05 ▲ beat |
| 2026-05-31 | USD 0.09 vs est 0.06 ▲ beat |
| 2026-02-28 | USD 0.09 vs est 0.05 ▲ beat |
| 2025-11-30 | USD 0.1 vs est 0.07 ▲ beat |
Source: Nexqual, October 23, 2026 at 21:05 UTC.
Financials & Fundamentals (NEOG)
| Total Revenue | $884.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +6.50% |
| Gross Margin | +47.40% |
| Operating Margin | -0.81% |
| Profit Margin | -6.35% |
| ROE | -2.67% |
| Debt / Equity | 0.37 |
| Current Ratio | 3.9 |
| Total Cash | $172.00M |
| Total Debt | $774.30M |
| Free Cash Flow (last four quarters to Aug 2026, SEC 10-Q / 10-K) | $49.80M (5.6% of revenue) |
Source: Nexqual, October 23, 2026 at 21:05 UTC.
Financial Health Score (NEOG)
Nexqual rates Neogen Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 21:05 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 47%, operating -1% (last 12 months) |
| Balance Sheet | Strong — $172M cash vs $774M debt |
| Cash Flow | Solid — FCF $50M (last 4 quarters to Aug 2026, SEC), 6% margin |
| Efficiency | Critical — ROE -3%, ROA -0.1% |
Ownership (NEOG)
| Insider Ownership | +0.76% |
|---|---|
| Institutional Ownership | +111.20% |
| Shares Outstanding | 218.31M |
| Float | 217.33M |
| Short % of Float | +7.25% |
Source: Nexqual, October 23, 2026 at 21:05 UTC.
Leadership (NEOG)
Neogen Corporation is led by Mikhael Nassif, CEO, President & Director, per Nexqual as of October 23, 2026 at 21:05 UTC.
| CEO, President & Director | Mikhael Nassif |
|---|---|
| CFO & Senior Vice President | R. Bryan Riggsbee |
| Chief Scientific Officer | Jeremy Yarwood |
| Senior Vice President of Manufacturing & Operations | Jim Walter |
Major Backers & Investors (NEOG)
Notable institutional backers of Neogen Corporation include Neuberger Berman Group, LLC, SG Americas Securities, LLC, T. Rowe Price, according to Nexqual as of October 23, 2026 at 21:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Neuberger Berman Group, LLC | 7.59% |
| SG Americas Securities, LLC | 4.28% |
| T. Rowe Price | 4.28% |
| ING Groep N.V. | 4.17% |
| Gates Capital Management, Inc. | 4% |
| BARON INVESTMENT Fd.S TRT -Baron Small Cap Fd. | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.31% |
| Vanguard Group | 10.39% |
| Dimensional Fund Advisors | 4.5% |
| State Street | 4.1% |
Source: Nexqual, October 23, 2026 at 21:05 UTC.
From Neogen Corporation's Latest SEC 10-K Filing (filed 2026-07-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We differentiate ourselves by offering planograms and convenient reordering systems to maximize turns and profitability for our retail customers.
Partnerships
- Certain technologies used in some products manufactured and marketed by Neogen were acquired from or developed in collaboration with partners, independent scientists, governmental agencies, universities and other third parties.
Legal & Regulatory Risks (Item 1A, quoted)
- Our reputation, ability to do business and results of operations could be impaired by improper conduct by or disputes with any of our employees, agents or business partners and we have a compliance burden with respect to, and risk of violations of, anti-bribery, trade control, trade sanctions, anti-corruption and similar laws.
- Evolving data privacy and data protection laws and regulations may increase our compliance costs and exposure to liability.
- The outcome of litigation, investigations, product recalls, and other legal proceedings in which we are involved is inherently uncertain; adverse developments could be costly, divert management attention, restrain insurance coverage, and materially harm our business, results of operation, financial condition, and cash flows.
- Our business may be subject to product or service liability claims.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TMDX | TransMedics Group, Inc. | USD 70.74 | ▼ 1.83% |
| UFPT | UFP Technologies, Inc. | USD 295.78 | ▼ 0.52% |
| AXGN | AxoGen, Inc. | USD 38.06 | ▲ 3.76% |
| INSP | Inspire Medical Systems, Inc. | USD 71.11 | ▼ 2.13% |
| ALMR | Alamar Biosciences, Inc. | USD 30.69 | ▲ 3.26% |
| ESTA | Establishment Labs Holdings Inc | USD 63.8 | ▲ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 21:05 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt